Primary Finding: Weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% compared with placebo (HR 0.80, 95% CI 0.720.90)
Its inhibitory actions may result from blockade of IGF1R signaling by binding IGF-1 and IGF-2, or through mechanisms independent of IGF1R, while its stimulatory actions are in some cases mediated through activation of sphingosine kinase 1 [17]
e.g., journaling, going for a walk in nature or phoning a friend
Goh KY, Lee WX, Choy SM, Priyadarshini GK, Chua K, Tan QH, Low SY, Chin HS, Wong CS, Huang SY, Fu NY, Nishiyama J, Harmston N, Tang HW
It helps with muscle building